117 related articles for article (PubMed ID: 1440514)
1. An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age.
Marder VJ; Shortell CK; Fitzpatrick PG; Kim C; Oxley D
Thromb Res; 1992 Jul; 67(1):31-40. PubMed ID: 1440514
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model.
Montoney M; Gardell SJ; Marder VJ
Circulation; 1995 Mar; 91(5):1540-4. PubMed ID: 7867196
[TBL] [Abstract][Full Text] [Related]
3. A bleeding model in rabbits demonstrate fresh clot selectivity for a genetically engineered variant of tissue-type plasminogen activator and for streptokinase.
Wikström K; Mattsson C; Pohl G
Thromb Res; 1993 May; 70(3):217-24. PubMed ID: 8392227
[TBL] [Abstract][Full Text] [Related]
4. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
Stewart D; Kong M; Novokhatny V; Jesmok G; Marder VJ
Blood; 2003 Apr; 101(8):3002-7. PubMed ID: 12446443
[TBL] [Abstract][Full Text] [Related]
5. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
Weitz JI
J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
[TBL] [Abstract][Full Text] [Related]
6. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
7. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.
Vanderschueren S; Collen D
Thromb Haemost; 1996 May; 75(5):816-9. PubMed ID: 8725729
[TBL] [Abstract][Full Text] [Related]
9. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
[TBL] [Abstract][Full Text] [Related]
10. Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.
Vaughan DE; Declerck PJ; De Mol M; Collen D
J Clin Invest; 1989 Aug; 84(2):586-91. PubMed ID: 2503540
[TBL] [Abstract][Full Text] [Related]
11. Haemostyptic effects of batroxobin with regard to hirudin treatment.
Markwardt F; Kaiser B; Richter M
Thromb Res; 1992 Dec; 68(6):475-82. PubMed ID: 1341058
[TBL] [Abstract][Full Text] [Related]
12. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
Fareed J; Walenga JM; Pifarre R; Hoppensteadt D; Koza M
Haemostasis; 1991; 21 Suppl 1():64-72. PubMed ID: 1894198
[TBL] [Abstract][Full Text] [Related]
13. Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotinin.
Garabedian HD; Gold HK; Leinbach RC; Svizzero TA; Finkelstein DM; Guerrero JL; Collen D
J Am Coll Cardiol; 1991 Apr; 17(5):1213-22. PubMed ID: 1706738
[TBL] [Abstract][Full Text] [Related]
14. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
Deschênes I; Finkle CD; Winocour PD
Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
Metz BK; White HD; Granger CB; Simes RJ; Armstrong PW; Hirsh J; Fuster V; MacAulay CM; Califf RM; Topol EJ
J Am Coll Cardiol; 1998 Jun; 31(7):1493-8. PubMed ID: 9626825
[TBL] [Abstract][Full Text] [Related]
16. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
17. DDAVP reduces bleeding during continued hirudin administration in the rabbit.
Bove CM; Casey B; Marder VJ
Thromb Haemost; 1996 Mar; 75(3):471-5. PubMed ID: 8701410
[TBL] [Abstract][Full Text] [Related]
18. Bolus thrombolysis in venous thromboembolism.
Agnelli G; Parise P
Chest; 1992 Apr; 101(4 Suppl):172S-182S. PubMed ID: 1555482
[TBL] [Abstract][Full Text] [Related]
19. Limiting systemic plasminogenolysis reduces the bleeding potential for tissue-type plasminogen activators but not for streptokinase.
Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Wu DT; Refino CJ; Keyt BA; Bennett WF
Thromb Haemost; 1996 Jun; 75(6):915-20. PubMed ID: 8822586
[TBL] [Abstract][Full Text] [Related]
20. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
